rs431905495
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000046.5(ARSB):c.1143-1G>C variant causes a splice acceptor change. The variant allele was found at a frequency of 0.00000248 in 1,612,948 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 6.8e-7 ( 0 hom. )
Consequence
ARSB
NM_000046.5 splice_acceptor
NM_000046.5 splice_acceptor
Scores
4
2
1
Splicing: ADA: 1.000
2
Clinical Significance
Conservation
PhyloP100: 4.92
Genes affected
ARSB (HGNC:714): (arylsulfatase B) Arylsulfatase B encoded by this gene belongs to the sulfatase family. The arylsulfatase B homodimer hydrolyzes sulfate groups of N-Acetyl-D-galactosamine, chondriotin sulfate, and dermatan sulfate. The protein is targeted to the lysozyme. Mucopolysaccharidosis type VI is an autosomal recessive lysosomal storage disorder resulting from a deficiency of arylsulfatase B. Two alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Dec 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, LoF is a know mechanism of disease, Cryptic splice site detected, with MaxEntScore 5.4, offset of 5, new splice context is: aaaattgttttccactgaAGgaa. Cryptic site results in frameshift change. If cryptic site found is not functional and variant results in exon loss, it results in frameshift change.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 5-78839427-C-G is Pathogenic according to our data. Variant chr5-78839427-C-G is described in ClinVar as [Pathogenic]. Clinvar id is 887.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr5-78839427-C-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ARSB | NM_000046.5 | c.1143-1G>C | splice_acceptor_variant | ENST00000264914.10 | NP_000037.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ARSB | ENST00000264914.10 | c.1143-1G>C | splice_acceptor_variant | 1 | NM_000046.5 | ENSP00000264914 | P1 | |||
ARSB | ENST00000396151.7 | c.1143-1G>C | splice_acceptor_variant | 1 | ENSP00000379455 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152084Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
152084
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 6.85e-7 AC: 1AN: 1460864Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 726766
GnomAD4 exome
AF:
AC:
1
AN:
1460864
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
726766
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152084Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74288
GnomAD4 genome
AF:
AC:
3
AN:
152084
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74288
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Mucopolysaccharidosis type 6 Pathogenic:8
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | The ARSB c.1143-1G>C variant occurs in a canonical splice site (acceptor) and is predicted to disrupt or distort the normal gene product. The c.1143-1G>C variant has been reported in four studies in which it is found in at least 14 individuals with mucopolysaccharidosis, type VI, including one who carried the variant in a homozygous state and 13, including two siblings, who carried the variant in a compound heterozygous state (Garrido et al. 2007; Karageorgos et al. 2007; Garrido et al. 2008; Giraldo et al. 2016). The clinical phenotypes of these patients ranged from intermediate to severe. The c.1143-1G>C variant was absent from 50 controls and is not found in the 1000 Genomes Project, the Exome Sequencing Project, or the Exome Aggregation Consortium. Functional studies showed that the variant resulted in lower levels of protein compared to wildtype, a range of 1-23% enzyme activity compared to controls, was subject to nonsense-mediated decay, and did not fully correctly localize to the lysosome (Karageorgos et al. 2007; Garrido et al. 2008). Based on the potential impact of splice acceptor variants and the evidence from the literature, the c.1143-1G>C variant is classified as pathogenic for mucopolysaccharidosis, type VI. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Dec 08, 2021 | - - |
Pathogenic, criteria provided, single submitter | curation | Laboratory of Diagnosis and Therapy of Lysosomal Disorders, University of Padova | Jan 01, 2018 | Splicing variant in canonical site (PVS1); In vitro functional studies supportive of a damaging effect on the gene product (demonstrated nonsense mediated RNA decay; PS3); Very low frequency in GnomAD (PM2); Reputable source identifies as pathogenic (PP5) - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 01, 2007 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 18, 2016 | Variant summary: The ARSB c.1143-1G>C variant substitutes a highly conserved nucleotide at the canonical splice acceptor site in intron 5. 4/5 splice prediction tools predict abrogation of the splice acceptor site. The prediction results are verified by a functional assay: RT-PCR on a patients fibroblasts showed skipping of exon 6 (Garrido_2007). Exon 6 is encodes a part of alkaline-phosphatase-like, core domain (InterPro), thus skipping of exon 6 is expected to form non-functional protein. This variant is absent in 121248 control chromosomes from the broad and large populations of ExAC. It is found in several patients with mucopolysaccharidosis type VI with consistent recessive genotypes including evidence of cosegregation with disease (Karageorgos_2007, Garrido_2007, and Garrido_2015). In addition, multiple clinical reputable databases have classified this variant as pathogenic. Taken together, this variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 11, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 15, 2023 | This sequence change affects an acceptor splice site in intron 5 of the ARSB gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs431905495, gnomAD 0.1%). Disruption of this splice site has been observed in individuals with mucopolysaccharidosis VI (PMID: 17458871). ClinVar contains an entry for this variant (Variation ID: 887). Studies have shown that disruption of this splice site results in exon 6 skipping and introduces a premature termination codon (PMID: 18406185). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Jul 26, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
MutationTaster
Benign
D;D;D
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AL_spliceai
Position offset: -1
Find out detailed SpliceAI scores and Pangolin per-transcript scores at